Psych MEQs / SAQs · Consultation-liaison psychiatry
Autoimmune encephalitis presenting as first-episode psychosis (MEQ)
FRANZCP-style MEQ on anti-NMDAR/autoimmune encephalitis red flags, work-up, immunotherapy, and psychiatry's role in FEP interface.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Red flags and differential. Red flags: subacute (days–weeks) first psychosis after viral-like prodrome; explosive tempo; speech reduction/mutism; orofacial dyskinesias; limited response to antipsychotics; young woman. Leading diagnosis: anti-NMDAR autoimmune encephalitis / probable autoimmune psychosis pending confirmation. Discriminators from primary FEP: rapid multistage evolution, hard neurologic signs (speech, movement), normal MRI does not exclude AE, need for EEG/CSF/Abs and immunotherapy rather than antipsychotic escalation alone.[1][6][4]
(ii) Investigations. Urgent neurology co-management. EEG (encephalopathic slowing; extreme delta brush supportive if present). MRI already done — normal MRI does not stop the pathway. LP: cell count, protein, glucose, OCB, infection panel including HSV PCR as indicated; paired serum and CSF neuronal cell-based assays (NMDAR and broader panel as advised). Do not rely on serum-only commercial tests. Metabolic baseline, pregnancy test. Tumour search: pelvic ultrasound/MRI for ovarian teratoma. Apply Graus possible/probable AE and Pollak frameworks to document rationale.[2][5][4]
(iii) Immunotherapy and tumour. When probable AE criteria are met, start first-line immunotherapy without waiting indefinitely for serology: high-dose IV methylprednisolone (commonly about 1 g daily for 3–5 days per local protocol), IVIG (commonly total 2 g/kg over 2–5 days), and/or plasma exchange (often about 5 exchanges). If inadequate response: second-line rituximab and/or cyclophosphamide under specialist protocols. Parallel teratoma resection if found — disease-modifying. Titulaer: early treatment and tumour removal improve outcomes.[3][5][6]
(iv) Psychotropics, capacity, family. Stop the "depot-only" plan. Use benzodiazepines for catatonia/agitation; cautious lowest-effective antipsychotic only for safety as a bridge — not definitive therapy. Assess capacity for LP/immunotherapy; if lacking, use local least-restrictive legal framework for emergency investigation/treatment (do not invent foreign section numbers). Explain to family: treatable brain inflammation, need for CSF and possible immunotherapy, hope for recovery over months with early care, psychiatry remains involved for symptoms and aftercare.[4][3][5]
Common errors
- Escalating depot antipsychotic as the main plan
- Treating normal MRI as exclusion of anti-NMDAR disease
- Serum-only antibody testing
- Waiting weeks for results before any immunotherapy when probable AE is clear
- Inventing Mental Health Act section numbers instead of stating principles
Examiner notes
High-scoring scripts name Graus, Pollak, Titulaer, and teratoma, and keep psychiatry's role as recognition + bridge + partnership rather than solo neuroimmunology. [2][3][4]
References
- [1]Herken J, Prüss H Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients Front Psychiatry, 2017.PMID 28261116
- [2]Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis Lancet Neurol, 2016.PMID 26906964
- [3]Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study Lancet Neurol, 2013.PMID 23290630
- [4]Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin Lancet Psychiatry, 2020.PMID 31669058
- [5]Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management J Neurol Neurosurg Psychiatry, 2021.PMID 33649022
- [6]Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies Lancet Neurol, 2008.PMID 18851928